摘要
目的:探讨恩替卡韦联合软肝化坚颗粒对CHB患者肝纤维化程度的影响,为临床治疗提供依据。方法:研究选取2014年5月~2018年10月于本院就诊的CHB肝纤维化86例,采用随机数字表法将患者分为研究组43例,对照组43例,两组患者在常规保肝治疗的基础上,对照组口服恩替卡韦治疗,研究组在对照组的基础上口服软肝化坚颗粒,检测分析两组患者治疗前后肝功能、血清肝纤维化四项指标、脾静脉、门静脉内径及Fibroscan肝脏硬度值,记录治疗期间所出现的不良反应及两组患者抗纤维化疗效。结果:研究组治疗后血清ALT、GGT分别为(26.3±10.6、24.8±11.3)U/L,显著低于对照组[(37.4±12.8、35.3±11.5)U/L]。研究组治疗后肝纤维化指标PC-Ⅲ、Ⅳ-C分别为(15.3±3.6、56.3±15.8)μg/mL,显著低于对照组[(25.3±5.4、97.4±18.3)μg/mL]。研究组抗纤维化总有效率为(90.7)%,显著高于对照组(72.1)%。研究组治疗后门静脉内径、脾静脉内径分别为(10.2±0.5、6.0±1.0)mm,显著低于对照组[(11.8±0.8、7.1±1.2)mm];研究组治疗后Fibroscan肝脏硬度值为(10.6±1.0)kPa,显著低于对照组[(16.3±1.3)kPa]。结论:恩替卡韦联合软肝化坚颗粒可有效缓解CHB患者的肝纤维化程度,联合用药效果要优于单独用药。
Objective To investigate the effect of entecavir combined with Ruangan Huajian Granule on the degree of liver fibrosis in patients with CHB,and to provide evidence for clinical treatment.Methods Eighty-six patients with CHB liver fibrosis who were admitted to our hospital from May 2014 to October 2018 were enrolled.The patients were divided into study group(43 cases)and control group(43 cases).The two groups were treated with conventional liver protection.On the basis of the treatment,the control group was treated with entecavir orally.The study group was treated with soft liver Huajian granule on the basis of the control group.The liver function and serum fibrosis were measured before and after treatment.The spleen vein,portal vein diameter and Fibroscan were detected.Liver hardness values were recorded for adverse reactions during treatment and anti-fibrotic effects in both groups.Results The serum ALT and GGT of the study group were(26.3±10.6,24.8±11.3)U/L,which was significantly lower than that of the control group[(37.4±12.8,35.3±11.5)U/L].The PC-III and IV-C indexes of the liver fibrosis in the study group were(15.3±3.6,56.3±15.8)μg/m L,which was significantly lower than that of the control group[(25.3±5.4,97.4±18.3)μg/m L].The total effective rate of anti-fibrosis in the study group was(90.7)%,which was significantly higher than that in the control group(72.1)%.The diameter of the portal vein and the diameter of the splenic vein in the study group were(10.2±0.5,6.0±1.0)mm,which was significantly lower than that of the control group[(11.8±0.8,7.1±1.2)mm];Fibroscan after treatment in the study group The liver hardness value was(10.6±1.0)kPa,which was significantly lower than that of the control group[(16.3±1.3)kPa].Conclusion Entecavir combined with Ruangan Huajian Granule can effectively treat the degree of liver fibrosis in patients with CHB,and the combined effect is better than that of the drug alone.
作者
曹德冠
王青平
Cao De-guan;Wang Qing-ping(Wanning People’s Hospital,Wanning 571500,China;Hainan Medical University The Second Affiliated Hospital,Haikou 570311,China)
出处
《湖南师范大学学报（医学版）》
2020年第1期5-8,共4页
Journal of Hunan Normal University(Medical Sciences)
基金
海南省自然科学基金(NO.818140).
